Rampant consolidation in nearly every state has created dominant health care systems that can use anticompetitive contracting practices to charge supracompetitive prices, especially to commercial insurance plans.
Author Archive for: johanna-butler
About Johanna Butler
Johanna Butler joined NASHP’s Emerging Policy Issues team in June 2018. She is involved with several projects related to lowering the cost of health care, focusing specifically on health system costs and prescription drug prices. She has also worked on advancing evidence-based policymaking through patient-centered outcomes research. Prior to joining NASHP, Johanna was an intern in the ranking member’s health policy office of the Senate Committee on Health, Education, Labor, and Pensions. She has also worked as the Lloyd Meeds Policy Fellow at K&L Gates and interned in the White House Office of Cabinet Affairs. Johanna graduated from American University in 2018 with an interdisciplinary studies degree focused on communications, law, economics, and government, and holds a certificate in Advanced Leadership Studies from the School of Public Affairs.
Entries by Johanna Butler
A new, independent analysis of the Montana state employee health plan’s transition to reference-based pricing – which limits hospital prices to a multiple of what Medicare pays – found significant savings for the state in the two years after its implementation. Further, there is no evidence that utilization artificially increased as a result of the new payment […]
In addition to providing critical funding for state COVID-19 response efforts, the American Rescue Plan requires drug manufacturers to pay more in Medicaid rebates for drugs with large price increases. This change, effective in 2024, has the potential to generate significant federal and state savings.
As states take important steps to lower prescription drug costs, at least six have implemented prescription drug affordability review initiatives, although approaches vary across states. The National Academy for State Health Policy (NASHP)’s new chart, Comparison of State Prescription Drug Affordability Review Initiatives, provides a road map of the diverse efforts taken by Maryland, Maine, […]
For more than a decade, Rhode Island has used a unique insurance rate review approach to keep hospital costs from rising any more than inflation plus 1 percent. As states confront COVID-19 and its accompanying budget crisis, Rhode Island’s approach that allows regulators to oversee hospital costs and requires insurers to invest in the state’s […]
To help state policymakers engage in difficult discussions around how best to lower the health care cost trajectory, the National Academy for State Health Policy created the slide deck, Understanding the Health Care Cost Conundrum in 2020, featuring factual information about rising health care costs. This toolbox features multiple sections that could be used together […]
COVID-19 and its impact on states’ economies and budgets has refocused attention on high health care costs. To help state policymakers engage in the difficult discussions around how best to lower the health care cost trajectory, the National Academy for State Health Policy (NASHP) created the slide deck Understanding the Health Care Cost Conundrum in […]
Last week, California Gov. Gavin Newsom signed SB 852, a law enabling California to become the first state to produce its own generic prescription drugs, an idea first proposed in the Governor’s 2020-2021 budget. The new law aims to reduce the cost of generic drugs by boosting competition and increase patient access to certain generics, […]
Six states with laws enabling the importation of prescription drugs from Canada – Vermont, Florida, Maine, Colorado, New Mexico, and New Hampshire – are awaiting publication of federal rules currently under review by the Office of Management and Budget. They are eager to see if the final rules address key concerns submitted by the National […]
Hospitals and health care providers need financial support to respond to the pandemic and for future viability. In response, Congress allocated billions of dollars in relief funds through multiple existing and new programs. The disbursement of these funds is uncoordinated and so are public reports that track where the money is going, but states need […]